To date, HDAC inhibitors have been utilized in the clinical setting and are considered to be therapeutic agents against tumour progression by causing cell cycle arrest, inducing cell death and inhibiting angiogenesis [177,178]. This evidence concerns the gene HDAC9 and neoplasm.